Stockscreener 앱 받기
86.57
6.09%
4.97
전일 마감가:
$81.60
열려 있는:
$82.01
하루 거래량:
881.09K
Relative Volume:
1.28
시가총액:
$4.47B
수익:
$379.25M
순이익/손실:
$-77.34M
주가수익비율:
-53.70
EPS:
-1.6122
순현금흐름:
$-27.87M
1주 성능:
+10.89%
1개월 성능:
+32.37%
6개월 성능:
+61.93%
1년 성능:
+106.12%
1일 변동 폭
$81.62
$86.79
1주일 범위
$73.82
$86.79
52주 변동 폭
$36.88
$86.79
Mirum Pharmaceuticals Inc Stock (MIRM) Company Profile
명칭
Mirum Pharmaceuticals Inc
전화
650-667-4085
주소
989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY
MIRM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MIRM
Mirum Pharmaceuticals Inc
|
86.57 | 4.22B | 379.25M | -77.34M | -27.87M | -1.6122 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mirum Pharmaceuticals Inc Stock (MIRM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-24 | 개시 | TD Cowen | Buy |
| 2025-08-11 | 재개 | Stifel | Buy |
| 2025-05-19 | 재개 | H.C. Wainwright | Buy |
| 2024-04-17 | 개시 | Stifel | Buy |
| 2023-12-18 | 재확인 | H.C. Wainwright | Buy |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-11-13 | 개시 | Morgan Stanley | Overweight |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-17 | 재개 | Evercore ISI | Outperform |
| 2023-09-20 | 개시 | JMP Securities | Mkt Outperform |
| 2022-09-01 | 개시 | Citigroup | Buy |
| 2021-09-20 | 개시 | JP Morgan | Overweight |
| 2020-08-07 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2020-08-03 | 개시 | H.C. Wainwright | Buy |
| 2020-07-31 | 개시 | Piper Sandler | Overweight |
| 2020-06-25 | 개시 | Robert W. Baird | Outperform |
| 2019-08-12 | 개시 | Citigroup | Buy |
| 2019-08-12 | 개시 | Evercore ISI | Outperform |
| 2019-08-12 | 개시 | Guggenheim | Buy |
| 2019-08-12 | 개시 | ROTH Capital | Buy |
| 2019-08-12 | 개시 | Raymond James | Outperform |
모두보기
Mirum Pharmaceuticals Inc 주식(MIRM)의 최신 뉴스
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Price Is Right But Growth Is Lacking After Shares Rocket 34% - 富途牛牛
Mirum Pharmaceuticals begins Phase 2 trial for Fragile X syndrome drug - Investing.com Nigeria
Can Mirum Pharmaceuticals Inc. stock maintain growth trajectoryJuly 2025 Update & High Conviction Buy Zone Alerts - ulpravda.ru
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals - Business Wire
MarketsMedicine Hat News - FinancialContent
Can Mirum Pharmaceuticals Inc. (08D) stock test all time highsTrade Performance Summary & Weekly Hot Stock Watchlists - ulpravda.ru
Is Mirum Pharmaceuticals Inc. (08D) stock undervalued after correctionJuly 2025 Institutional & Risk Managed Investment Entry Signals - ulpravda.ru
Will Mirum Pharmaceuticals Inc. stock benefit from infrastructure spendingWeekly Stock Report & Risk Controlled Daily Plans - ulpravda.ru
How supply chain issues affect Mirum Pharmaceuticals Inc. stockJuly 2025 Action & Fast Gaining Stock Reports - ulpravda.ru
Can Mirum Pharmaceuticals Inc. stock reach $100 price targetQuarterly Profit Review & Risk Adjusted Buy/Sell Alerts - ulpravda.ru
Mirum Pharmaceuticals to raise $68.5M in private placement with TCGX - MSN
Mirum Pharmaceuticals stock hits all-time high at 82.65 USD By Investing.com - Investing.com Nigeria
How Investors May Respond To Mirum Pharmaceuticals (MIRM) Expanding Livmarli And Gaining J.P. Morgan Spotlight - Yahoo Finance
Is Mirum Pharmaceuticals Inc. stock supported by strong fundamentalsInstitutional Holding Changes & High Return Investment Plans - ulpravda.ru
Mirum Pharmaceuticals, Inc.common stock (NQ: MIRM - FinancialContent
How Mirum Pharmaceuticals Inc. stock compares to growth peersMorning Star Patterns & Free Skyrocketing Profit Margins - ulpravda.ru
Should you invest in Mirum Pharmaceuticals (MIRM)? - MSN
Mirum Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
Mirum Pharmaceuticals stock hits all-time high at 82.65 USD - Investing.com India
What hedge fund activity signals for Mirum Pharmaceuticals Inc. stockEarnings Date Calendar & Low Cost Trading Plans - ulpravda.ru
Mirum Pharmaceuticals (MIRM) price target increased by 16.25% to 104.35 - MSN
Should You Invest in Mirum Pharmaceuticals (MIRM)? - Insider Monkey
Mirum Pharmaceuticals, Inc. (MIRM) Stock Analysis: A 36.45% Potential Upside Captivates Investors - DirectorsTalk Interviews
Gains Recap: Will Mirum Pharmaceuticals Inc stock benefit from infrastructure spendingWeekly Investment Summary & Short-Term High Return Strategies - moha.gov.vn
Mirum Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update - ADVFN
Mirum Pharmaceuticals Earnings Notes - Trefis
Mirum Pharmaceuticals (NASDAQ:MIRM) Downgraded by Wall Street Zen to "Buy" - MarketBeat
Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update - ADVFN
Aug Reactions: Will Mirum Pharmaceuticals Inc. stock pay special dividendsStop Loss & Reliable Volume Spike Alerts - moha.gov.vn
Price-Driven Insight from (MIRM) for Rule-Based Strategy - Stock Traders Daily
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows Strong Growth Momentum and Bullish Technical Setup - Chartmill
Prediction: 3 Stocks That Will Be Worth More Than Newsmax 5 Years From Now - Finviz
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line - Yahoo Finance
Why a Top Biotech Holder Sold 115,000 Mirum Shares but Still Ended Up With $185 Million on the Line - The Motley Fool
Rice Hall James & Associates LLC Sells 67,247 Shares of Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals price target raised to $88 from $80 at Baird - MSN
What Analysts Think Is Changing the Story for Mirum Pharmaceuticals Now - Yahoo Finance
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Mirum pharmaceuticals director Saira Ramasastry sells $400k in shares By Investing.com - Investing.com Nigeria
Mirum Pharma director Grey sells $3.9 million in stock By Investing.com - Investing.com Nigeria
Mirum pharmaceuticals director Saira Ramasastry sells $400k in shares - Investing.com
Mirum Pharmaceuticals Executives Sell Shares - TradingView — Track All Markets
Mirum Pharma director Grey sells $3.9 million in stock - Investing.com
This Biotech Name Outperforms 93% Of Stocks, And It's In A Buy Zone - Investor's Business Daily
Mirum Pharmaceuticals joins elite list of stocks with 95-plus composite rating - MSN
Guidance Update: Will Mirum Pharmaceuticals Inc 08D stock sustain uptrend momentumPortfolio Return Summary & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Mirum Pharmaceuticals: Rich In 2025, Richer (In Promise) In 2026? I Believe So (MIRM) - Seeking Alpha
Mirum: Maintaining Buy Rating On VOLIXIBAT PSC Treatment Data Q2 2026 (NASDAQ:MIRM) - Seeking Alpha
Squarepoint Ops LLC Decreases Stock Holdings in Mirum Pharmaceuticals, Inc. $MIRM - MarketBeat
Mirum Pharmaceuticals Inc (MIRM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.90%
자본화:
|
볼륨(24시간):